Business
QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth
VENLO, Netherlands, January 12, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and automation system innovations to support its goal for $2 billion of combined annual pillar sales in 2028.
About this update from Qiagen N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":242,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/0e356abd784c1d5eaca2cd067d03c608"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ePrBfl5Usv9KpPdKSI_SJw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTM1NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0e356abd784c1d5eaca2cd067d03c608","width":242,"height":204}},"lazy":false},{"type":"text","content":"Building on strong momentum in 2025, new product launches and regulatory milestones planned for 2026 to support goal of at least $2 billion in combined annual pillar sales in 2028","length":179,"tagName":"p","attribs":{}},{"type":"text","content":"VENLO, Netherlands, January 12, 2026--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and automation system innovations to support its goal for $2 billion of combined annual pillar sales in 2028.","length":357,"tagName":"p"},{"type":"text","content":"Following strong operational execution in 2025, QIAGEN enters 2026 with plans for new product launches and submissions among its pillars designed to expand addressable markets, increase its installed base of automation systems and strengthen recurring consumables and software revenues across the continuum from life sciences to diagnostics customers.","length":351,"tagName":"p"},{"type":"text","content":"The five pillars – Sample technologies, QIAstat-Dx syndromic testing, QIAcuity digital PCR, QIAGEN Digital Insights (QDI) bioinformatics and QuantiFERON for latent tuberculosis testing – represent areas where QIAGEN has established leadership and scaling differentiated platforms with growth potential.","length":302,"tagName":"p"},{"type":"text","content":""We delivered on key targets in 2025 and enter 2026 with strong momentum," said Thierry Bernard, CEO of QIAGEN. "Our investments we are making in automation, menu expansion and AI, together with targeted and differentiated acquisitions, are designed to accelerate growth, advancing in high-value areas of life sciences and diagnostics and sharpening our competitive edge as we move toward achieving our 2028 ambitions."...